Protocol Ledger

NCT03714815 · Phase II · TERMINATED

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Interventional Phase II clinical trial protocol NCT03714815 sponsored by Johnson & Johnson / Janssen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-07 Enrollment: 91 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03714815
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)91 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03714815
Protocol FieldVerified Registry Value
NCT IdentifierNCT03714815
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment91 participants (ACTUAL)
Registered Start Date2018-12-07
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI